Selpercatinib may alter the landscape of RET-altered cancers
23 Oct 2020
bởiAudrey Abella
The novel, next-generation, highly potent and selective RET inhibitor selpercatinib may modify the landscape of another genomic subgroup — RET-altered cancers, according to two early-phase trials investigating the potential of selpercatinib in medullary thyroid cancer (MTC) and non-small-cell lung cancer (NSCLC).